Navigation Links
PrimeraDx Appoints Albert A. Luderer to its Board of Directors
Date:9/22/2011

MANSFIELD, Mass., Sept. 22, 2011 /PRNewswire/ -- PrimeraDx today announced that Albert Luderer has been appointed to its Board of Directors.  

President and CEO Matthew McManus commented:  "We are excited to have Al join our board at this pivotal time.  We have just launched the ICEPlex System, which is the first molecular diagnostics system that is capable of high multiplex, multi-modal qPCR, and Al brings many years of experience in the commercialization of innovative products.  Al's established track record of commercializing diagnostic technologies will provide PrimeraDx with great strategic vision as we bring personalized medicine to the clinic."

Dr. Luderer has over 30 years of leadership experience in diagnostics, therapeutics and research tools companies.  He currently serves as CEO and Board Member at Integrated Diagnostics.  Dr. Luderer has served as President, CEO, and Director at BioTrove (acquired by Life Technologies), CEO and Director of Light Sciences Inc, President and COO at bioMerieux Inc, VP of R&D and Business Development at Dianon Systems (now Lab Corp), VP of Technology Development and Support at Boehringer Mannheim (now Roche), and Head of Biomedical Research for Ciba Corning.  Dr. Luderer earned a PhD from Rutgers University.

"I am very enthusiastic about PrimeraDx and the core technology behind the ICEPlex platform.  The ability to both run a high multiplex reaction and receive a quantitative result is very timely," Commented Dr. Luderer.  "I believe that PrimeraDx is positioned to lead the next generation of molecular diagnostics technology with their all-in-one well solution."

About PrimeraDx

PrimeraDx is dedicated to the high growth field of molecular diagnostics.  The Company has developed a unique platform for high-multiplex, quantitative, real-time PCR based on its proprietary STAR technology, implemented on the walk-away ICEPlex® instrument system.  PrimeraDx is developing a broad range of applications in oncology, infectious disease, companion diagnostics and multiple non-clinical molecular markets, both through its own efforts and in collaboration with partners.  The Company is backed by a strong group of experienced venture-capital investors, including Abingworth, InterWest Partners, CHL Medical Partners, and Malaysia Technology Development Corporation.  The Company's website is: www.primeradx.com or www.multiplexpcr.com.

CONTACT: Andrew Bond, +1-508-618-2752, abond@primeradx.com


'/>"/>
SOURCE PrimeraDx
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. PrimeraDx Names Fayyaz Memon Vice President of Regulatory Affairs and Quality Assurance
2. Neurologix Appoints Adrian Adams as Company Chairman and Chief Executive Officer
3. Planet Biopharmaceuticals, Inc. Appoints Theron (Ted) Odlaug, Ph.D. as Executive Chairman
4. 3-V Biosciences Appoints George W. Kemble, PhD, as Chief Scientific Officer
5. Creabilis Appoints Dr David Roblin as Chief Medical Officer
6. MRIGlobal Appoints Richard A. Winegar, Ph.D., as Principal Advisor for Science
7. Amsterdam Molecular Therapeutics Appoints Dr. Carlos R. Camozzi as Chief Medical Officer
8. Imagenetix, Inc. Appoints Bill Toomey to Its Board of Directors
9. Oramed Pharmaceuticals Appoints Dr. Michael Berelowitz as Chairman of Scientific Advisory Board
10. Crescendo Biologics Appoints Matthew Roe as Chief Business Officer
11. Synthetic Genomics Inc. Appoints Joseph Mahler as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... , Dec. 2, 2016 Amgen (NASDAQ: ... ) today announced the submission of a Marketing Authorization Application ... a biosimilar candidate to Avastin ® (bevacizumab). The companies ... to the EMA. "The submission of ABP ... seeks to expand our oncology portfolio," said Sean E. ...
(Date:12/2/2016)... ... , ... ACEA Biosciences, Inc. announced today that it will be presenting updated ... World Conference on Lung Cancer 2016, taking place in Vienna, Austria December 3rd-8th. ... for AC0010 in patients with advanced non-small cell lung cancer harboring the EGFR T790M ...
(Date:12/2/2016)... ... December 01, 2016 , ... ... (CSS) and the popularity of US Single Day Events (SDE) to organize a ... Summer 2018, in Raleigh, NC. Topics of the pharmaceutical and life sciences industry ...
(Date:12/2/2016)... IL (PRWEB) , ... December 01, 2016 , ... ... to congratulate long-term client Nanowear on their recent FDA Class II 510(k) clearance ... cleared a significant hurdle in commercializing remote cardiac monitoring devices that rely on ...
Breaking Biology Technology:
(Date:11/22/2016)... Minn. , Nov. 22, 2016   MedNet ... supports the entire spectrum of clinical research, is pleased ... Medical LiveWire Healthcare and Life Sciences Awards ... award caps off an unprecedented year of recognition and ... trials for over 15 years. iMedNet ...
(Date:11/17/2016)... , Nov. 17, 2016 Global Market Watch: ... Public Biobanks (Disease-Based Banks, Population-Based Banks and Academics) market is ... analysis for Private Biobanks shows the highest Compounded Annual Growth ... region during the analysis period 2014-2020. ... CAGR of 9.95% followed by Europe ...
(Date:11/15/2016)... , Nov. 15, 2016  Synthetic Biologics, ... developing therapeutics focused on the gut microbiome, today ... of 25,000,000 shares of its common stock and ... stock at a price to the public of ... to Synthetic Biologics from the offering, excluding the ...
Breaking Biology News(10 mins):